Expression of PD‐L1 and CTLA‐4 in female urethral carcinoma

INTRODUCTION: Although the tumors are often easily detected, a considerable number of patients with female urethral carcinoma are diagnosed in an advance stage. Thus, no evidence‐based therapeutic approach has been established. We herein report our experience in the treatment of three female patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Ninomiya, Sahoko, Kawahara, Takashi, Mochizuki, Taku, Ishiguro, Yukari, Miyoshi, Yasuhide, Otani, Masako, Yao, Masahiro, Miyamoto, Hiroshi, Uemura, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292119/
https://www.ncbi.nlm.nih.gov/pubmed/32743365
http://dx.doi.org/10.1002/iju5.12029
Descripción
Sumario:INTRODUCTION: Although the tumors are often easily detected, a considerable number of patients with female urethral carcinoma are diagnosed in an advance stage. Thus, no evidence‐based therapeutic approach has been established. We herein report our experience in the treatment of three female patients with urethral carcinoma. We also examined the expression of PD‐L1 and CTLA‐4. CASE PRESENTATION: Three female patients pathologically diagnosed with urethral carcinoma, including urothelial carcinoma, squamous cell carcinoma, and adenocarcinoma, between 2013 and 2017 were analyzed in this study. Two patients underwent urethrectomy with cystostomy. Immunohistochemistry was performed to assess the levels of PD‐L1 and CTLA‐4 expression in patients with urethral carcinoma. Eleven control cases of urethral carcinoma tissue were also stained. CONCLUSION: This study revealed the expression of PD‐L1 and CTLA‐4 in female urethral carcinomas.

Ejemplares similares